Obesity is a multifactorial disease associated with hypertension. In the obese population, the incidence 19 of hypertension is high and resistant hypertension is commonly observed. Mechanisms to explain the 20 resistance to current anti-hypertensive treatments are still poorly understood. Emerging knowledge of 21 the role of aldosterone in controlling blood pressure in obesity may have therapeutic benefit. 22
Introduction 29
Obesity affects 1/3 of the adult US population and is commonly associated with hypertension, a need for 30 a higher number of antihypertensive medications, and an increased likelihood of never achieving blood 31 pressure control (1, 3) . The Framingham study showed that excess weight account for up to 75% of the 32 risk for hypertension (78% for men, 64% for women) (13) and that losing weight is effective to reduce 33 blood pressure (18). However lifestyle modifications are poorly followed and medications are generally 34 required to reduce blood pressure. The current guidelines from the American Heart Association 35 recommend the use of ACEi/ARBs/diuretics as a primary line of treatment for hypertension in both lean 36 and obese populations. Epidemiologic studies have shown that this course of action is not effective for 37 obese patients (19). Recent studies have reported the presence of increased levels of aldosterone in the 38 obese population, independently of the renin-angiotensin system (24). Additionally, basic and clinical 39 observations report the efficacy of aldosterone inhibition on blood pressure control in obese patients 40 (6). Despite these observations, aldosterone inhibitors are rarely utilized in the control of hypertension. 41 This review will summarize clinical studies reporting the superior efficacy of MR (mineralocorticoid 42 receptor) blockers in the treatment of hypertension and resistant hypertension in the obese population. 43
Concurrently, we will show that obesity is strongly associated with increased aldosterone. 44
Hypertension in obesity 45
The mechanisms linking obesity and increased blood pressure are not well elucidated and numerous 46 hypotheses have been reported. Obesity drives sympathetic nervous system hyperactivity, impaired 47 renal function, increased levels of aldosterone and angiotensin II, insulin metabolism, and induced 48 sodium retention, all potentially leading to hypertension (14, 16) . Due to the absence of clear 49 physiologic links between obesity and blood pressure, the American Heart Association recommends 50 same therapeutic approaches for the treatment of lean and obese hypertensive patients (additionally to 51 life style changes). Data from the Hypertension and Diabetes Risk Screening and Awareness (HYDRA) 52 study, a cross-sectional study of 45,125 primary care patients, reported that patients with a body mass 53 index >40 kg/m2 had a higher prevalence of hypertension, as well as higher probability of requiring 4 54 (5.3 fold increase) or 3 (3.2 fold) antihypertensive drugs, to achieve blood pressure control compared 55 with patients with normal weight (BMI ≤25 kg/m2)(19). In the recent Antihypertensive and Lipid-56
Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) study, only 30% of patients had their blood 57 pressure controlled at year 5 (1, 10). Resistant hypertension, defined by a blood pressure level that 58 remains above goal in spite of the use of 3 optimally dosed antihypertensive medications of different 59 classes, has a higher prevalence in the obese population (3, 19) . Despite these reports, there are few 60 studies looking at the appropriateness of current guidelines for hypertension treatment in the obese 61 population. 62
High levels of aldosterone in overweight/obese patients 63
Aldosterone is a hormone synthesized in the zona glomerulosa of the adrenal glands in response to 64 angiotensin II and increases in plasma potassium, principally, and to a lower extent to the 65 adrenocorticotropin hormone. Recent works highlighted the importance of the adipose tissue as new 66 source of aldosterone (4) as well as a producer of yet un-identified factor(s) (7, 23) promoting 67 aldosterone release. It is generally accepted that obesity is associated with inappropriately high 68 aldosterone levels. As early as 1981, a study showed that weight loss in an obese population was 69 associated with decrease aldosterone (24). Numerous studies followed looking at plasma and urine 70 aldosterone levels, in the overweight and obese populations (5). These studies revealed a relationship 71 between BMI and plasma aldosterone concentration, apparently influenced by factors such as fat 72 distribution, lipidemia, insulin resistance and kidney disease. Human studies looking at sub-types of 73 obese populations are especially likely to find a relationship between BMI and aldosterone levels; a clear 74 link has been demonstrated in obese women (15), in a population from African descent (2) and in class 2 75 and 3 obese patients (21). This relationship is non-existent in lean population (BMI <26.6 kg.m -2 ) (25). 76
Effectiveness of aldosterone inhibition in obesity 77
The guidelines from the American Heart Association on the treatment of hypertension recommend 78 using mineralocorticoid receptor (MR) inhibitors as a fourth line of medication. One of the reasons cited 79 for delayed initiation of MR therapy was the concern that a potential increase in plasma potassium (K + ) 80 associated with the treatment could lead to fatal arrhythmia (22). A recent study on the use of MR 81 inhibitors showed that only few patients have increased K + and that plasma K + can be easily controlled 82
by regular blood samples, dose adjustment in the first few weeks of treatment (17), or addition of a 83 diuretic (12). Several studies have looked at the effect of adding spironolactone or epleronone to classic 84 treatment (ACEi/ARBs/diuretics) to treat hypertension and resistant hypertension in obese 85 population (6, 8, 11, 20) . No increase in mortality due to K + -arrythmias was observed in the groups 86 receiving aldosterone inhibitors. Results showed a significant decrease in blood pressure, but specific 87 studies must be conducted to determine the efficacy of aldosterone inhibition and the potential benefit 88 of using it as the first line of treatment. A pilot study conducted by Costa et al. (9) on 11 obese 89 hypertensive subjects showed the efficacy of spironolactone in controlling blood pressure but the small 90 sample size is a limitation. We discussed above that plasma aldosterone concentration varies within the 91 obese population; this could be a limit to the efficacy of MR blockade. Together these data highlight the 92 limits of the extrapolation of the results gathered in the lean population, in term of drug efficacy and 93 stress the need for more basic and clinical studies testing the efficacy of therapies in the obese 94 population, specifically. In addition, further studies are also required to determine the source of the 95 inappropriately high plasma aldosterone exhibited by obese patients. Confirmation of contribution of 96 aldosterone to obesity-associated hypertension should likely lead to a change in the guidelines on the 97 treatment of hypertension and to the use of MR blockers as a first line of treatment in patients with 98 inappropriately high aldosterone levels (Fig. 1) . 99
Perspectives and significance 101
Prevalence of obesity is predicted to grow across the globe in the next few decades. Treatments for 102 hypertension, one of the most common side effects of obesity, represent a cost of billions of dollars. 103
Current treatments were developed in the lean population and the efficacy was not studied in the 104 subset of overweight/obese population. Resistant hypertension has a high prevalence in the obese 105 population and to date there remains a lack of complete understanding of the mechanisms involved in 106 the regulation of the blood pressure in obesity. Our review showed the basic and clinical evidences for 107 using aldosterone inhibitors as a first-line option for controlling blood pressure in the obese population. 108
Additionally to control more efficiently hypertension, reducing the number of drugs needed to achieve 109 blood pressure control (Fig.1 ) will reduce the health care burden and increase the compliance and 110 quality of life of the obese population. 111 112
